Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Valeant Pharmaceuticals
Valeant Pharmaceuticals
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
You need to be a subscriber to read this article.
Click here
to find out more.
Media
A precision medicine approach to developing cancer vaccines
Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Design & Build
Valeant Canada expands with $27.5m investment
The company will expand manufacturing and exporting capacity in Steinbach, Manitoba and Laval, Quebec
Valeant Pharmaceuticals names Joseph Papa as Chairman and Chief Executive
He brings more than 30 years of leadership and operations experience in healthcare to the firm
Valeant Pharmaceuticals makes management change
In its US Dermatology and Gastrointestinal businesses
J. Michael Pearson returns as CEO of Valeant following illness
Robert A. Ingram appointed Chairman of the Board as the roles of Chairman and CEO are separated
Regulatory
Opinion: Politics, passion and patient power
Did political correctness play a greater role than therapeutic efficacy in the FDA's decision to approve the 'pink Viagra'?
Subscribe now